The drug, called lecanemab, met the study's main and secondary goals, reducing clinical decline over 18 months compared to a ...
The CEO resuscitated the sector’s first “public benefit corporation” during the pandemic, building an unusually transparent ...
Rival companies have set a standard in lymphoma and leukemia. Now the Swiss drugmaker wants to be a pioneer in cell ...
A former Biogen employee sued in 2012, alleging the company paid physician fees to encourage prescribing of its drugs. Biogen ...
The company and its development partner, CRISPR Therapeutics, will begin submitting a so-called rolling application in ...
The California biotech company will receive $25 million upfront from Sanofi, which plans to use Scribe’s platform to edit ...
The startup, which launched last year with $315 million in funding and plans to advance a new form of gene editing, is one of ...
The request, if cleared, would make U.S. kids between 5 through 11 eligible to receive a "bivalent" shot targeting components ...
The U.K. drugmaker now also stands to become the first big pharmaceutical company to have women in its top two roles, with ...
While a long-rumored acquisition by Merck & Co. still hasn’t materialized, Seagen is forging ahead with a deal of its own, ...
With supply and labor constraints creating backlogged custom-manufacturing schedules, developers have felt the pain in cost ...
The drug, meant to complement other treatments for paroxysmal nocturnal hemoglobinuria, comes via Alexion, which had acquired ...